drugset / Trial / NCT01496365

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365

Phase 2 Completed 452 enrolled Daiichi Sankyo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and effectiveness of DS-5565 compared to placebo (inactive substance) and pregabalin in diabetic subjects with DPN.

Timeline

Start
2011-11-28
Primary completion
2012-09-07
Completion
2012-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirogabalin Small molecule 5 mg
Subject Mirogabalin Small molecule 10 mg
Subject Mirogabalin Small molecule 15 mg
Subject Mirogabalin Small molecule 20 mg
Subject Mirogabalin Small molecule 30 mg
Comparator Pregabalin Small molecule 300 mg